ArticleThe Journal of clinical investigation2015
Immunosurveillance and therapy of multiple myeloma are CD226 dependent.
Article in The Journal of clinical investigation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Review
- Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization.Signal transduction and targeted therapy · 2024Review
- Article
- Immune status and selection of patients for immunotherapy in myeloma: a proposal.Blood advances · 2024Review
- Clearing soluble MIC reverses the impaired function of natural killer cells from patients with multiple myeloma.Journal for immunotherapy of cancer · 2024Article
- The immune system in multiple myeloma and precursor states: Lessons and implications for immunotherapy and interception.American journal of hematology · 2023Review
- CHST12: a potential prognostic biomarker related to the immunotherapy response in pancreatic adenocarcinoma.Frontiers in endocrinology · 2023Article
- Hierarchical transcriptional network governing heterogeneous T cell exhaustion and its implications for immune checkpoint blockade.Frontiers in immunology · 2023Review
- Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma.Journal of hematology & oncology · 2022Review
- Toll-like receptor 4 selective inhibition in medullar microenvironment alters multiple myeloma cell growth.Blood advances · 2022Article
- Single-cell RNA-sequencing reveals distinct immune cell subsets and signaling pathways in IgA nephropathy.Cell & bioscience · 2021Article
- T cell landscape and dynamics in immunoglobulin light chain amyloidosis before and after daratumumab-based therapy.Clinical and translational medicine · 2021Article
- Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy.Blood cancer discovery · 2021Article
- Laboratory Mice - A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma.Frontiers in immunology · 2021Review
- Cytokine-Mediated Dysregulation of Signaling Pathways in the Pathogenesis of Multiple Myeloma.International journal of molecular sciences · 2020Review
- Bone Marrow Stromal Cell-Derived IL-8 Upregulates PVR Expression on Multiple Myeloma Cells via NF-kB Transcription Factor.Cancers · 2020Article
- Review
- Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease.Science translational medicine · 2019Article
- A Natural Impact: NK Cells at the Intersection of Cancer and HIV Disease.Frontiers in immunology · 2019Review
- NK Cell Dysfunction and Checkpoint Immunotherapy.Frontiers in immunology · 2019Review
Corrections and comments
- Erratum forImmunosurveillance and therapy of multiple myeloma are CD226 dependent.2015 · Chesi, Martha [corrected to Chesi, Marta]
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.